<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2946">
  <stage>Registered</stage>
  <submitdate>6/10/2010</submitdate>
  <approvaldate>6/10/2010</approvaldate>
  <nctid>NCT01218659</nctid>
  <trial_identification>
    <studytitle>Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease</studytitle>
    <scientifictitle>A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>AT1001-012</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Fabry Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - migalastat hydrochloride
Other interventions - agalsidase

Active Comparator: Enzyme Replacement Therapy - 

Experimental: AT1001 - 


Treatment: drugs: migalastat hydrochloride
oral AT1001 capsules and inactive reminder capsules taken every day

Other interventions: agalsidase
intravenous infusion in accordance with the local approved product labeling

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>renal function assessed by iohexol Glomerular Filtration Rate (GFR)</outcome>
      <timepoint>18 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>renal function (assessed by estimated GFR and 24-hour urine protein)</outcome>
      <timepoint>18 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>composite clinical outcome (assessed by time to occurrence of renal, cardiac, cerebrovascular events or death)</outcome>
      <timepoint>18 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>cardiac function (assessed by echocardiography)</outcome>
      <timepoint>18 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>patient reported outcomes (pain and quality of life)</outcome>
      <timepoint>18 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female between the ages of 16 and 74 diagnosed with Fabry disease

          -  Confirmed GLA mutation that has shown to be responsive to AT1001 in vitro

          -  Subject has been on ERT for at least 12 months before Visit 2

          -  Dose level and regimen of ERT have been stable for 3 months before Visit 2 and is at
             least 80% of the currently labeled dose and regimen for this time period

          -  GFR = 30mL/min/1.73 m2

          -  Subjects taking angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor
             blockers (ARBs) must be on a stable dose for at least 4 weeks before Visit 1

          -  Women who can become pregnant and all men agree to be sexually abstinent or use
             medically accepted methods of birth control throughout the duration of the study and
             for up to 30 days after last dose of study medication

             * For sites in Italy: Women who can become pregnant and all men, agree to plan (or
             have their partner plan) with his/her physician a birth control strategy (or method)
             in order to avoid pregnancy throughout the duration of the study and for up to 30 days
             after the last dose of study medication

          -  Subject is willing and able to provide written informed consent and assent if
             applicable</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>74</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subject has undergone, or is scheduled to undergo, kidney transplantation or any other
             solid organ transplantation

          -  Subject is on regular dialysis that is specifically for the treatment of chronic
             kidney disease

          -  Subject has had a documented transient ischemic attack, stroke, unstable angina, or
             myocardial infarction within the 3 months before Visit 1

          -  Subject has clinically significant unstable cardiac disease in the opinion of the
             investigator (e.g., cardiac disease requiring active management, such as symptomatic
             arrhythmia, unstable angina, or NYHA class III or IV congestive heart failure)

          -  Pregnant or breast-feeding

          -  History of allergy or sensitivity to study medication (including excipients) or other
             iminosugars (e.g., miglustat, miglitol)

          -  Subject has absolute contraindication to iohexol and/or inability to undergo iohexol
             GFR testing

          -  Subject requires treatment with Glyset® (miglitol), or Zavesca® (miglustat)

          -  Subject received any investigational/experimental drug, biologic or device within 30
             days of Visit 1

          -  Any intercurrent illness or condition that may preclude the subject from fulfilling
             the protocol requirements or suggests to the investigator that the subject may have an
             unacceptable risk by participating in this study

          -  Otherwise unsuitable for the study, in the opinion of the investigator</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>60</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode>3065 - Parkville</postcode>
    <postcode>6000 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Catamarca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Pergamino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerpen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Porto Alegre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Copenhagen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Garches</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Firenze</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Niigata</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Osaka City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Osaka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zurich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Ankara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cambridge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Salford</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amicus Therapeutics</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Study to compare the efficacy and safety of AT1001 and enzyme replacement therapy (ERT) in
      male and female patients with Fabry disease who are currently receiving ERT and who have
      AT1001-responsive GLA mutations.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01218659</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Monitor Clinical Research</name>
      <address>Amicus Therapeutics</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>